Cargando…

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series

Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prasad, Femin, De, Riddhita, Korann, Vittal, Chintoh, Araba F., Remington, Gary, Ebdrup, Bjørn H., Siskind, Dan, Knop, Filip Krag, Vilsbøll, Tina, Fink-Jensen, Anders, Hahn, Margaret K., Agarwal, Sri Mahavir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126648/ https://www.ncbi.nlm.nih.gov/pubmed/37113745 http://dx.doi.org/10.1177/20451253231165169

Ejemplares similares

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

S89. INVESTIGATING METABOLIC DYSFUNCTION AND METABOLOMIC PROFILE CHANGES IN ANTIPSYCHOTIC NAIVE PATIENTS
por: Costa-Dookhan, Kenya, et al.
Publicado: (2020)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
por: Raben, Alex T., et al.
Publicado: (2018)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
por: Kanagasundaram, Pruntha, et al.
Publicado: (2021)

M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY
por: Mahavir Agarwal, Sri, et al.
Publicado: (2020)

Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
por: Stogios, Nicolette, et al.
Publicado: (2021)

Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
por: Stogios, Nicolette, et al.
Publicado: (2023)

Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis
por: Wu, Sally, et al.
Publicado: (2023)

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
por: Ebdrup, Bjørn H, et al.
Publicado: (2012)

Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
por: Agarwal, Sri Mahavir, et al.
Publicado: (2021)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study
por: Lee, Jiwon, et al.
Publicado: (2023)

Effect of Betahistine and Metformin on Antipsychotic-Induced Weight Gain: An Analysis of Two Clinical Trials
por: Kang, Dongyu, et al.
Publicado: (2018)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
por: Hausner, Helene, et al.
Publicado: (2017)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis
por: de Silva, Varuni Asanka, et al.
Publicado: (2016)

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
por: Vilsbøll, Tina, et al.
Publicado: (2018)

Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area
por: Høgnason Mohr, Grimur, et al.
Publicado: (2023)

Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
por: Bækdal, Tine A., et al.
Publicado: (2019)

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020)

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials
por: Storgaard, Heidi, et al.
Publicado: (2014)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bowden, Sylvie, et al.
Publicado: (2020)

The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study
por: Hakami, Alqassem Y., et al.
Publicado: (2022)

Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls
por: Stogios, Nicolette, et al.
Publicado: (2022)

S225. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OR PREVENTION OF WEIGHT GAIN IN SCHIZOPHRENIA
por: Agarwal, Sri Mahavir, et al.
Publicado: (2018)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
por: Singh, Raghunath, et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2
por: Shabeer, D, et al.
Publicado: (2022)

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
por: Kumar, K B Sharan, et al.
Publicado: (2022)

Value of gym-based group exercise versus usual care for young adults receiving antipsychotic medication: study protocol for the multicenter randomized controlled Vega trial
por: Rafn, Bolette Skjødt, et al.
Publicado: (2023)

S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE
por: Agarwal, Sri Mahavir, et al.
Publicado: (2020)

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
por: de Boer, Nini, et al.
Publicado: (2021)

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)
por: Sass, Marie Reeberg, et al.
Publicado: (2023)

Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis
por: Zhuo, Chuanjun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hovsflqqmcpmj0c406bsvqc0a0